Evidence map›Paper›PMID 29335428›Full record

ArticleScientific reports2018

Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.

Dhoha Triki, Mario Enrique Cano Contreras, Delphine Flatters, Benoit Visseaux, Diane Descamps, Anne-Claude Camproux, Leslie Regad

Abstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dhoha TrikiMolécules thérapeutiques in silico (MTi), INSERM UMR-S973, Paris, France.
Mario Enrique Cano ContrerasMolécules thérapeutiques in silico (MTi), INSERM UMR-S973, Paris, France.
Delphine FlattersMolécules thérapeutiques in silico (MTi), INSERM UMR-S973, Paris, France.
Benoit VisseauxIAME, INSERM UMR 1137, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France.ORCID http://orcid.org/0000-0002-9279-5538
Diane DescampsIAME, INSERM UMR 1137, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France.
Anne-Claude CamprouxMolécules thérapeutiques in silico (MTi), INSERM UMR-S973, Paris, France.
Leslie RegadMolécules thérapeutiques in silico (MTi), INSERM UMR-S973, Paris, France. leslie.regad@univ-paris-diderot.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HIV-2 protease (PR2) is a homodimer of 99 residues with asymmetric assembly and binding various ligands. We propose an exhaustive study of the local structural asymmetry between the two monomers of all available PR2 structures complexed with various inhibitors using a structural alphabet approach. On average, PR2 exhibits asymmetry in 31% of its positions-i.e., exhibiting different backbone local conformations in the two monomers. This asymmetry was observed all along its structure, particularly in the elbow and flap regions. We first differentiated structural asymmetry conserved in most PR2 structures from the one specific to some PR2. Then, we explored the origin of the detected asymmetry in PR2. We localized asymmetry that could be induced by PR2's flexibility, allowing transition from the semi-open to closed conformations and the asymmetry potentially induced by ligand binding. This latter could be important for the PR2's adaptation to diverse ligands. Our results highlighted some differences between asymmetry of PR2 bound to darunavir and amprenavir that could explain their differences of affinity. This knowledge is critical for a better description of PR2's recognition and adaptation to various ligands and for a better understanding of the resistance of PR2 to most PR2 inhibitors, a major antiretroviral class.

Indexed as

CarbamatesCrystallography, X-RayDarunavirEnzyme InhibitorsFuransHIV ProteaseProtein BindingProtein ConformationProtein SubunitsSulfonamidesamprenavirCarbamatesDarunavirEnzyme InhibitorsFuransHIV Proteasep16 protease, Human immunodeficiency virus 2Protein SubunitsSulfonamides

Identifiers

PMID29335428
PMCPMC5768731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.